👥 Chime Biologics will support stable cell line development and manufacturing for clinical trials.
💉 The candidate, DT-7012, aims to activate anti-tumor immunity and is expected to start phase I clinical studies in 2025.
🤝 Both companies are excited about the partnership and the potential of this immunotherapy treatment.
Introduction:
Domain Therapeutics and Chime Biologics have entered into a manufacturing service agreement for Domain’s anti-CCR8 antibody candidate, DT-7012, which aims to provide an effective therapeutic for cancer patients. Chime Biologics will be responsible for stable cell line development and candidate manufacturing to support clinical trials in various countries.
- Domain Therapeutics and Chime Biologics have signed a manufacturing service agreement for the production of Domain’s anti-CCR8 antibody candidate, DT-7012.
- Chime Biologics will ensure stable cell line development and manufacturing to support clinical trials in strategic countries.
- DT-7012 is an anti-CCR8 monoclonal antibody that depletes tumor-infiltrating Tregs, which are major immunosuppressive cells.
- Phase I clinical studies of DT-7012 are expected to start in early 2025 for solid tumors and mid-2025 for cutaneous T-cell lymphoma (CTCL).
- The partnership between Domain Therapeutics and Chime Biologics aims to advance the development of DT-7012 for various cancers and unlock the immune system’s cancer-fighting abilities.
Conclusion:
Domain Therapeutics and Chime Biologics have joined forces to advance the development of DT-7012, an anti-CCR8 antibody candidate for cancer immunotherapy. With Chime Biologics’ expertise in stable cell line development and manufacturing, this partnership aims to deliver an effective therapeutic option for cancer patients worldwide. The phase I clinical studies of DT-7012, expected to begin in 2025, hold promise for treating solid tumors and cutaneous T-cell lymphoma. This collaboration showcases the potential of GPCR-targeting immunotherapies in activating anti-tumor immunity and offers hope for patients unresponsive to other treatments.
